TWI814903B - 咪唑吡啶酮化合物 - Google Patents

咪唑吡啶酮化合物 Download PDF

Info

Publication number
TWI814903B
TWI814903B TW108133054A TW108133054A TWI814903B TW I814903 B TWI814903 B TW I814903B TW 108133054 A TW108133054 A TW 108133054A TW 108133054 A TW108133054 A TW 108133054A TW I814903 B TWI814903 B TW I814903B
Authority
TW
Taiwan
Prior art keywords
group
reference example
methyl
alkyl
title compound
Prior art date
Application number
TW108133054A
Other languages
English (en)
Chinese (zh)
Other versions
TW202024077A (zh
Inventor
森山彰
滝川靖
Original Assignee
日商橘生藥品工業股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商橘生藥品工業股份有限公司 filed Critical 日商橘生藥品工業股份有限公司
Publication of TW202024077A publication Critical patent/TW202024077A/zh
Application granted granted Critical
Publication of TWI814903B publication Critical patent/TWI814903B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
TW108133054A 2018-09-13 2019-09-12 咪唑吡啶酮化合物 TWI814903B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018-171839 2018-09-13
JP2018171839 2018-09-13

Publications (2)

Publication Number Publication Date
TW202024077A TW202024077A (zh) 2020-07-01
TWI814903B true TWI814903B (zh) 2023-09-11

Family

ID=69777067

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108133054A TWI814903B (zh) 2018-09-13 2019-09-12 咪唑吡啶酮化合物

Country Status (24)

Country Link
US (2) US12077531B2 (https=)
EP (1) EP3808747B1 (https=)
JP (1) JP7458987B2 (https=)
KR (1) KR102830577B1 (https=)
CN (1) CN112689637B (https=)
AR (1) AR116400A1 (https=)
AU (1) AU2019340173B2 (https=)
BR (1) BR112021004730A2 (https=)
CA (1) CA3106385A1 (https=)
DK (1) DK3808747T3 (https=)
ES (1) ES3016010T3 (https=)
FI (1) FI3808747T3 (https=)
HU (1) HUE069830T2 (https=)
IL (1) IL281391B2 (https=)
MX (1) MX2021003027A (https=)
MY (1) MY207239A (https=)
NZ (1) NZ773786A (https=)
PH (1) PH12021550512A1 (https=)
PL (1) PL3808747T3 (https=)
PT (1) PT3808747T (https=)
SG (1) SG11202102441VA (https=)
TW (1) TWI814903B (https=)
WO (1) WO2020054788A1 (https=)
ZA (1) ZA202101671B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7414550B2 (ja) * 2020-01-23 2024-01-16 キッセイ薬品工業株式会社 (ヘテロ)アリールイミダゾロン化合物
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
CA3169000A1 (en) * 2020-03-11 2021-09-16 Hideki Takeuchi Crystal of imidazopyridinone compound or salt thereof
JP7654426B2 (ja) * 2020-03-12 2025-04-01 キッセイ薬品工業株式会社 イミダゾピリジノン化合物の製造方法
CN117402178B (zh) * 2023-12-15 2024-03-08 英矽智能科技(上海)有限公司 作为jak抑制剂和phd抑制剂的嘧啶类化合物
WO2025264818A1 (en) * 2024-06-20 2025-12-26 Raythera, Inc. Stat6 modulators and methods of uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107145A (zh) * 1993-11-02 1995-08-23 赫彻斯特股份公司 取代的杂环羧酰胺、它们的制备及作为药物的应用
WO2009134750A1 (en) * 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
WO2009137291A2 (en) * 2008-05-08 2009-11-12 Merck & Co., Inc. Spiroazaindoles
US20110077267A1 (en) * 2009-07-17 2011-03-31 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
WO2016148306A1 (en) * 2015-03-18 2016-09-22 Takeda Pharmaceutical Company Limited Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713474B2 (en) 1998-09-18 2004-03-30 Abbott Gmbh & Co. Kg Pyrrolopyrimidines as therapeutic agents
CA2344249A1 (en) * 1998-09-18 2000-03-30 Basf Aktiengesellschaft Pyrrolopyrimidines as protein kinase inhibitors
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
WO2003037890A2 (en) 2001-11-01 2003-05-08 Icagen, Inc. Piperidines
MXPA06000700A (es) * 2003-07-23 2006-04-11 Wyeth Corp Compuestos de sulfonildihidroimidazopiridinona como ligandos de 5-hidroxitriptamina-6.
US7749999B2 (en) 2003-09-11 2010-07-06 Itherx Pharmaceuticals, Inc. Alpha-ketoamides and derivatives thereof
ATE531705T1 (de) * 2004-05-18 2011-11-15 Schering Corp Substituierte 2-chinolyloxazole geeignet als pde4 inhibitoren
EP1861377B1 (en) 2005-03-15 2010-12-29 Pfizer, Inc. Benzimidazolone derivatives as cb2 receptor ligands
DE102005019712A1 (de) 2005-04-28 2006-11-09 Bayer Healthcare Ag Dipyridyl-dihydropyrazolone und ihre Verwendung
WO2007015877A2 (en) * 2005-07-20 2007-02-08 Kalypsys, Inc. Inhibitors of p38 kinase and methods of treating inflammatory disorders
US20070142369A1 (en) 2005-12-21 2007-06-21 Margaret Van Heek Combination of an H3 antagonist/inverse agonist and an appetite suppressant
US20090298811A1 (en) 2006-09-12 2009-12-03 Pfizer Inc Benzimidazolone derivatives
EP2160187B1 (en) 2007-05-16 2013-05-22 Merck Sharp & Dohme Corp. Spiroindalones
CA2686485A1 (en) * 2007-05-23 2008-11-27 Pharmacopeia, Llc Purinones and 1h-imidazopyridinones as pkc-theta inhibitors
CA2698071A1 (en) 2007-08-27 2009-03-05 Wyeth Llc Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
CN101951777A (zh) * 2008-02-25 2011-01-19 默沙东公司 四氢呋喃并吡啶酮
EP2364313B1 (en) 2008-09-09 2014-01-08 Boehringer Ingelheim International GmbH Aza-benzimidazolone chymase inhibitors
JP2011037814A (ja) 2009-08-14 2011-02-24 Synstar Japan Co Ltd マラリア原虫疾患予防又は治療用の5−ヘテロ環置換イミノ−9−ジアルキルアミノベンゾ[a]フェノキサチン化合物又はその塩とアーテミシニン誘導体との組み合わせ
WO2011096490A1 (ja) 2010-02-04 2011-08-11 第一三共株式会社 イミダゾピリジン-2-オン誘導体
FR2967355B1 (fr) * 2010-11-17 2013-09-27 Jouvin Jean Luc Seringue dentaire securisee
WO2014181813A1 (ja) 2013-05-10 2014-11-13 武田薬品工業株式会社 複素環化合物
EP3056975B1 (en) 2013-10-08 2020-08-12 Maxell, Ltd. Projection type image display device, manipulation detection device and projection type image display method
WO2015052675A1 (en) 2013-10-10 2015-04-16 Glenmark Pharmaceuticals S.A. Substituted dihydro-benzimidazole compounds as ror gamma modulators
CN104926733B (zh) 2014-03-18 2019-05-10 北京韩美药品有限公司 作为RORγ调节剂的化合物
UA124090C2 (uk) * 2015-06-03 2021-07-21 Прінсіпіа Байофарма Інк. Інгібітори тирозинкінази
EP3414234B1 (en) 2015-10-14 2022-06-29 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
RU2743126C9 (ru) 2016-08-22 2021-04-27 Шицзячжуан Сагесити Нью Драг Дивелопмент Ко., Лтд. Ингибитор pde4
US10899758B2 (en) * 2016-09-16 2021-01-26 Vitae Pharmaceuticals, Llc Inhibitors of the menin-MLL interaction
CA3087886A1 (en) * 2018-01-19 2019-07-25 Idorsia Pharmaceuticals Ltd C5a receptor modulators

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1107145A (zh) * 1993-11-02 1995-08-23 赫彻斯特股份公司 取代的杂环羧酰胺、它们的制备及作为药物的应用
WO2009134750A1 (en) * 2008-04-28 2009-11-05 Janssen Pharmaceutica Nv Benzoimidazoles as prolyl hydroxylase inhibitors
WO2009137291A2 (en) * 2008-05-08 2009-11-12 Merck & Co., Inc. Spiroazaindoles
US20110077267A1 (en) * 2009-07-17 2011-03-31 Japan Tobacco Inc. Triazolopyridine compound, and action thereof as prolyl hydroxylase inhibitor or erythropoietin production-inducing agent
WO2016148306A1 (en) * 2015-03-18 2016-09-22 Takeda Pharmaceutical Company Limited Fused bicyclic heteroaryl derivatives having activity as phd inhibitors

Also Published As

Publication number Publication date
IL281391A (en) 2021-04-29
IL281391B2 (en) 2025-04-01
AU2019340173A1 (en) 2021-04-08
US20240425504A1 (en) 2024-12-26
SG11202102441VA (en) 2021-04-29
MY207239A (en) 2025-02-08
JP7458987B2 (ja) 2024-04-01
CA3106385A1 (en) 2020-03-19
ZA202101671B (en) 2022-07-27
US12077531B2 (en) 2024-09-03
PT3808747T (pt) 2025-01-30
KR102830577B1 (ko) 2025-07-08
AU2019340173B2 (en) 2024-02-08
ES3016010T3 (en) 2025-05-08
IL281391B1 (en) 2024-12-01
EP3808747A1 (en) 2021-04-21
WO2020054788A1 (ja) 2020-03-19
NZ773786A (en) 2025-09-26
TW202024077A (zh) 2020-07-01
MX2021003027A (es) 2021-05-27
EP3808747B1 (en) 2024-12-18
CN112689637A (zh) 2021-04-20
EP3808747A4 (en) 2022-03-09
CN112689637B (zh) 2023-11-10
US20210206765A1 (en) 2021-07-08
FI3808747T3 (fi) 2025-02-07
AR116400A1 (es) 2021-05-05
KR20210057014A (ko) 2021-05-20
JPWO2020054788A1 (ja) 2021-08-30
HUE069830T2 (hu) 2025-04-28
BR112021004730A2 (pt) 2021-06-01
PL3808747T3 (pl) 2025-03-17
PH12021550512A1 (en) 2022-02-21
DK3808747T3 (da) 2025-02-03

Similar Documents

Publication Publication Date Title
TWI814903B (zh) 咪唑吡啶酮化合物
JP7579789B2 (ja) 免疫調節剤、組成物およびその使用方法
CN108349940B (zh) 布鲁顿酪氨酸激酶抑制剂
TWI864112B (zh) 一類具有brd4抑制活性的化合物、其製備方法及用途
WO2010058846A1 (ja) 4,6-ジアミノニコチンアミド化合物
TW200539858A (en) Amido compounds and their use as pharmaceuticals
WO2021115457A1 (zh) 吡唑并[1,5-a]吡啶类化合物及其制备方法和应用
CA2922933A1 (en) 2,8-diazaspiro[4.5]decane and 3,9-dispiro[5.5]undecane derivates and pharmaceutical compositions thereof useful as tryptophan hydroxylase inhibitors
TW201444821A (zh) 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
CA2988209A1 (en) Spiro[cyclobutane-1,3'-indolin]-2'-one derivatives as bromodomain inhibitors
JP6859358B2 (ja) テトラヒドロインダゾール及びその医学的使用
AU2019291490B2 (en) Cyanotriazole compounds and uses thereof
CN108884103A (zh) 作为免疫调节剂的三并环化合物
TW202134213A (zh) 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
JP7504822B2 (ja) イミダゾピリジノン化合物を含む医薬組成物
CN115427407A (zh) 一种新型n-杂环bet溴结构域抑制剂、其制备方法及医药用途
JP7654426B2 (ja) イミダゾピリジノン化合物の製造方法
JP7414550B2 (ja) (ヘテロ)アリールイミダゾロン化合物
TW201934558A (zh) 苯并雜芳基類衍生物、其製備方法及其在醫藥上的應用
HK40050961A (en) Imidazopyridinone compound
HK40050961B (zh) 咪唑并吡啶酮化合物
EA047234B1 (ru) Иммуномодуляторы, композиции и способы с их использованием
HK40105522A (zh) Parp1抑制剂及其用途